# Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia

> **NCT02072811** · PHASE3 · UNKNOWN · sponsor: **dr hab. n. med. Agnieszka Wierzbowska** · enrollment: 400 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** DAC
- **DRUG:** CLAG
- **DRUG:** Consolidation, I HAM cycle
- **DRUG:** II Consolidation HiDAraC
- **DRUG:** Consolidation, III HiDAraC cycle

## Key facts

- **NCT ID:** NCT02072811
- **Lead sponsor:** dr hab. n. med. Agnieszka Wierzbowska
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-02
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2014-02-27

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02072811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02072811, "Role of the Therapy Tailored to Risk Factors in Treating Adult Patients (≤60) With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02072811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*